A股收評:深成指、創業板指微跌,滬指升0.38%,可控核聚變、CRO板塊爆發
A股主要指數今日早盤走高,午後回落;截至收盤,滬指升0.38%報3348點,深證成指跌0.01%,創業板指跌0.09%。全天成交1.15萬億元,較前一交易日縮量905億元,全市場超3800股上升。盤面上,醫藥板塊集體走強,CRO板塊、創新藥、生物製品等方向領升,和元生物、科倫藥業等多股升停;可控核聚變板塊爆發,合鍛智能等多股升停;超導概念走強,西部超導領升;醫療器械、輔助生殖及電力等板塊升幅居前。另外,騰訊雲概念下挫,長亮科技跌超7%;機器人板塊持續低迷,日發精機跌超8%;智譜AI板塊走弱,思美傳媒跌超5%;貴金屬、國資雲概念及東數西算等板塊跌幅居前。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.